Cardeas Pharma specializes in early phase development of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms. By combining novel formulations of proven antibiotics with cutting edge drug delivery technology, Cardeas is addressing significant unmet medical needs in the critical-care setting.

News

Cardeas Pharma Completes $34 Million in Series B Financing

Seattle, May 22, 2013 - Cardeas Pharma Corporation, a biopharmaceutical company focused on the development of innovative therapies for the treatment of multi-drug resistant (MDR) bacterial infections, announced today the completion of a $34 million Series B round of financing.  The round was led by new investor H.I.G. BioVentures,…

Read More